We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having+1q. For patients with+1q, the overall response rate to induction was 85%, with 40% havingVGPR and 20% achieving a CR, similar to non+1q patients (p=.64). The median PFS from diagnosis with+1q was 2.1 years (95% CI: 1.2-not reached (NR)) vs 4.3 years (95% CI: 3.3 yrs-NR) without+1q (p=.003). Median OS from diagnosis was 4.4 years (95% CI: 2.9-NR) vs not reached, respectively (p=.005). On molecular analysis using the Foundation One Heme assay, the most common mutations seen in+1q patients included TP53 (38%) and KRAS (25%). Overall, gain of 1q portends worse PFS and OS which was not negated by auto HCT. Such patients will likely require additional therapy to improve their survival.